On Jan 12, 2026, ARGX reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of 6.30 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 1.31 billion, with a --% difference. The market reacted with a +1.82% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 11 analysts forecast an EPS of 6.64 USD, with revenue projected to reach 1.32 billion USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Anixa Biosciences, Inc.
Report Date
Jan 12, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.09
Surprise
-0.78%
Lexaria Bioscience Corp. Common Stock
Report Date
Jan 13, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.07
Surprise
+47.21%
FAQ
What were argenx SE - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, argenx SE - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to argenx SE - ADR's Q4 2025 earnings?
The stock price moved up 1.82%, changed from $796.00 before the earnings release to $810.51 the day after.
When is argenx SE - ADR expected to report next?
The next earning report is scheduled for May 07, 2026.
What are the forecasts for argenx SE - ADR's next earnings report?
Based on 11
analysts, argenx SE - ADR is expected to report EPS of $6.64 and revenue of $1.32B for Q1 2026.